January 31, 2019 Feature

Jury Selection: The Often-Overlooked Make-It-or-Break-It Phase of a Trial

By Dick Semerdjian and Janice Mulligan

The jury selection process in the trial of Martin Shkreli, the CEO of Mylan Pharmaceuticals, the company that raised the price of EpiPen, “an emergency allergy injection sold by Mylan,” lasted three days.1 “Shkreli was widely criticized for defending the 400 percent increase in the price of EpiPen. . . . More than two hundred potential jurors were excused from the trial.”2 Here are a few examples of the court’s voir dire:

Premium Content For:
  • Tort Trial and Insurance Practice Section
Join - Now